These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20489055)

  • 21. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
    Li L; An LC; Chu XX; Liu XQ; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
    Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
    Grossmann V; Kohlmann A; Eder C; Haferlach C; Kern W; Cross NC; Haferlach T; Schnittger S
    Leukemia; 2011 May; 25(5):877-9. PubMed ID: 21339759
    [No Abstract]   [Full Text] [Related]  

  • 28. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
    Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
    Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
    Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
    Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Lee IK; Kim NY; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim N; Yoshida K; Ogawa S; Kim DD
    Haematologica; 2015 Sep; 100(9):e351-3. PubMed ID: 26045292
    [No Abstract]   [Full Text] [Related]  

  • 33. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical Significance of Truncated Mutant ΔJBP of TET2 Gene in Patients with Acute Myeloid Leukemia].
    Yang YC; Xia T; Luo M; Guo WZ; Zhang LL; Chen XH; Xu ZF; Wang HW; Tan YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1011-1018. PubMed ID: 34362476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
    Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
    Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
    Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 40. Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array.
    Villa O; Mallo M; Kosyakova N; Salido M; Liehr T; Martínez-Avilés L; Pedro C; García-Aragonés M; Espinet B; Bellosillo B; Florensa L; Arenillas L; Cuscó I; Jurado LA; Solé F
    Leuk Res; 2011 Sep; 35(9):e161-3. PubMed ID: 21684005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.